Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| NRX Pharmaceuticals, Inc.NRXP · Entity 6523 | Interim CEO | March 08, 2022 | March 10, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
NRX Pharmaceuticals, Inc.
Report date March 08, 2022 · Filed March 10, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Employee Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $2.61 · Expires 2032-03-08 | Direct | 347,200 |
Reported balance
After 2022-03-08 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-03-08 · Grant · Acquired 100,000 · Balance 347,200 F1: Options issued under the NRX Pharmaceuticals, Inc. 2021 Omnibus Incentive Plan. The options vest on March 8, 2023, generally subject to the Reporting Person's continued service for NRX Pharmaceuticals, Inc. |
Filing footnotes · ownership attribution and instrument terms
F1: Options issued under the NRX Pharmaceuticals, Inc. 2021 Omnibus Incentive Plan. The options vest on March 8, 2023, generally subject to the Reporting Person's continued service for NRX Pharmaceuticals, Inc.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 08, 2022 Filed Mar 10, 2022 16:04 UTC | NRX Pharmaceuticals, Inc. NRXP · Entity 6523 | GrantEmployee Stock Option · Derivative | 100,000 | $2.61 Strike: $2.61 | $261,000.00 |
DisclosureSEC source: 0000950142-22-000997 · es220233694_4-besthof.xml · derivative · entry 1 Besthof Robert · CIK 0001864650 · Interim CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 347,200 Underlying: Common Stock · 100,000 shares Expires 2032-03-08 F1 · derivative.exercise_date: Options issued under the NRX Pharmaceuticals, Inc. 2021 Omnibus Incentive Plan. The options vest on March 8, 2023, generally subject to the Reporting Person's continued service for NRX Pharmaceuticals, Inc. Read SEC document |
| September 15, 2021 Filed Nov 2, 2021 16:04 UTC | NRX Pharmaceuticals, Inc. NRXP · Entity 6523 | SaleCommon Stock | 40,000 | $11.76 | $470,400.00 |
DisclosureSEC source: 0000950142-21-003503 · es210197021_4-besthof.xml · nonDerivative · entry 2 Besthof Robert · CIK 0001864650 · Chief Comm. & Patient Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,710 Read SEC document |
| August 16, 2021 Filed Nov 2, 2021 16:04 UTC | NRX Pharmaceuticals, Inc. NRXP · Entity 6523 | GrantRestricted Stock Units · Derivative | 36,290 | $0.00 | $0.00 |
DisclosureSEC source: 0000950142-21-003503 · es210197021_4-besthof.xml · derivative · entry 4 Besthof Robert · CIK 0001864650 · Chief Comm. & Patient Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,290 Underlying: Common Stock · 36,290 shares Expires not disclosed F2 · derivative.exercise_price: Shares and restricted stock units acquired pursuant to the exercise of 100,000 vested stock options under the NRX Pharmaceuticals, Inc. 2021 Omnibus Incentive Plan (the "Plan"). The Reporting person received 63,701 freely tradable shares of common stock, par value $0.001 per share, of NRX Pharmaceuticals, Inc. (the "Common Stock") and 36,290 restricted stock units, each restricted stock unit representing a right to receive one share of Common Stock. The restricted stock units remain in the Plan and are subject to forfeiture if the Earnout Share Milestone and the Earnout Cash Milestone (as defined in the Merger Agreement) do not occur on or prior to December 31, 2022. F2 · shares: Shares and restricted stock units acquired pursuant to the exercise of 100,000 vested stock options under the NRX Pharmaceuticals, Inc. 2021 Omnibus Incentive Plan (the "Plan"). The Reporting person received 63,701 freely tradable shares of common stock, par value $0.001 per share, of NRX Pharmaceuticals, Inc. (the "Common Stock") and 36,290 restricted stock units, each restricted stock unit representing a right to receive one share of Common Stock. The restricted stock units remain in the Plan and are subject to forfeiture if the Earnout Share Milestone and the Earnout Cash Milestone (as defined in the Merger Agreement) do not occur on or prior to December 31, 2022. F2 · derivative.exercise_date: Shares and restricted stock units acquired pursuant to the exercise of 100,000 vested stock options under the NRX Pharmaceuticals, Inc. 2021 Omnibus Incentive Plan (the "Plan"). The Reporting person received 63,701 freely tradable shares of common stock, par value $0.001 per share, of NRX Pharmaceuticals, Inc. (the "Common Stock") and 36,290 restricted stock units, each restricted stock unit representing a right to receive one share of Common Stock. The restricted stock units remain in the Plan and are subject to forfeiture if the Earnout Share Milestone and the Earnout Cash Milestone (as defined in the Merger Agreement) do not occur on or prior to December 31, 2022. F2 · derivative.expiration_date: Shares and restricted stock units acquired pursuant to the exercise of 100,000 vested stock options under the NRX Pharmaceuticals, Inc. 2021 Omnibus Incentive Plan (the "Plan"). The Reporting person received 63,701 freely tradable shares of common stock, par value $0.001 per share, of NRX Pharmaceuticals, Inc. (the "Common Stock") and 36,290 restricted stock units, each restricted stock unit representing a right to receive one share of Common Stock. The restricted stock units remain in the Plan and are subject to forfeiture if the Earnout Share Milestone and the Earnout Cash Milestone (as defined in the Merger Agreement) do not occur on or prior to December 31, 2022. Read SEC document |
| August 16, 2021 Filed Nov 2, 2021 16:04 UTC | NRX Pharmaceuticals, Inc. NRXP · Entity 6523 | ConversionEmployee Stock Option (Right to buy) · Derivative | 100,000 | $0.20 Strike: $0.20 | $20,000.00 |
DisclosureSEC source: 0000950142-21-003503 · es210197021_4-besthof.xml · derivative · entry 3 Besthof Robert · CIK 0001864650 · Chief Comm. & Patient Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 247,200 Underlying: Common Stock · 100,000 shares Expires 2026-03-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The options are fully vested. Read SEC document |
| August 16, 2021 Filed Nov 2, 2021 16:04 UTC | NRX Pharmaceuticals, Inc. NRXP · Entity 6523 | Exercise / conversionCommon Stock | 63,710 | $0.20 | $12,742.00 |
DisclosureSEC source: 0000950142-21-003503 · es210197021_4-besthof.xml · nonDerivative · entry 1 Besthof Robert · CIK 0001864650 · Chief Comm. & Patient Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,710 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · acquired: The options are fully vested. Read SEC document |
| May 24, 2021 Filed Jun 10, 2021 18:44 UTC | NRX Pharmaceuticals, Inc. NRXP · Entity 6523 | GrantEmployee Stock Option (Right to buy) · Derivative | 347,200 | Not disclosed Strike: $3.08 | Not disclosed |
DisclosureSEC source: 0000950142-21-001936 · es210157180_4-besthof.xml · derivative · entry 2 Besthof Robert · CIK 0001864650 · Chief Comm. & Patient Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 347,200 Underlying: Common Stock · 347,200 shares Expires 2030-10-23 F2 · price: Subject to certain conditions, the options will generally vest in five equal installments of 20% on each of 10/23/21, 10/23/22, 10/23/23, 10/23/24 and 10/23/25. F1 · derivative.exercise_date: Pursuant to the Merger Agreement, each option and warrant of NeuroRx that was outstanding and unexercised immediately prior to the Effective Time was assumed by NRX Pharmaceuticals (each, a "Substitute Security") and represents the right to acquire an adjusted number of shares of Common Stock at an adjusted exercise price, in each case, pursuant to the terms of the Merger Agreement. In the event that any Substitute Security is exercised prior to the earlier of the date on which both the Earnout Share Milestone and the Earnout Cash Milestone (as defined in the Merger Agreement) have been achieved and December 31, 2022, a number of shares of the Issuer's common stock will be subject to forfeiture pursuant to the Option Post-Earnout Adjustment (as defined in the Merger Agreement). F2 · derivative.exercise_date: Subject to certain conditions, the options will generally vest in five equal installments of 20% on each of 10/23/21, 10/23/22, 10/23/23, 10/23/24 and 10/23/25. Read SEC document |
| May 24, 2021 Filed Jun 10, 2021 18:44 UTC | NRX Pharmaceuticals, Inc. NRXP · Entity 6523 | GrantEmployee Stock Option (Right to buy) · Derivative | 347,200 | Not disclosed Strike: $0.21 | Not disclosed |
DisclosureSEC source: 0000950142-21-001936 · es210157180_4-besthof.xml · derivative · entry 1 Besthof Robert · CIK 0001864650 · Chief Comm. & Patient Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 347,200 Underlying: Common Stock · 347,200 shares Expires 2026-03-01 F2 · price: Subject to certain conditions, the options will generally vest in five equal installments of 20% on each of 10/23/21, 10/23/22, 10/23/23, 10/23/24 and 10/23/25. F1 · derivative.exercise_date: Pursuant to the Merger Agreement, each option and warrant of NeuroRx that was outstanding and unexercised immediately prior to the Effective Time was assumed by NRX Pharmaceuticals (each, a "Substitute Security") and represents the right to acquire an adjusted number of shares of Common Stock at an adjusted exercise price, in each case, pursuant to the terms of the Merger Agreement. In the event that any Substitute Security is exercised prior to the earlier of the date on which both the Earnout Share Milestone and the Earnout Cash Milestone (as defined in the Merger Agreement) have been achieved and December 31, 2022, a number of shares of the Issuer's common stock will be subject to forfeiture pursuant to the Option Post-Earnout Adjustment (as defined in the Merger Agreement). Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.